Published in J Nucl Med on September 01, 2003
[18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging (2004) 1.61
Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer. Eur J Nucl Med Mol Imaging (2007) 1.53
18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging (2007) 1.25
Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging (2008) 1.17
Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) and 3'-[18F]fluoro-3'-deoxythymidine (FLT). Mol Imaging Biol (2007) 1.14
Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe. J Biol Chem (2011) 1.10
Brain tumors. Semin Nucl Med (2012) 1.05
Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells. J Nucl Med (2010) 1.00
PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice. J Clin Invest (2010) 1.00
Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging. Leuk Res (2010) 1.00
Methodology for quantitative rapid multi-tracer PET tumor characterizations. Theranostics (2013) 0.98
Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging (2004) 0.97
3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. J Nucl Med (2013) 0.97
The role of nucleoside/nucleotide transport and metabolism in the uptake and retention of 3'-fluoro-3'-deoxythymidine in human B-lymphoblast cells. Nucl Med Biol (2011) 0.92
Assessment of cellular proliferation in tumors by PET using 18F-ISO-1. J Nucl Med (2013) 0.90
Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol (2012) 0.86
3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer. PLoS One (2014) 0.83
The role of 18F-FLT in cancer imaging: does it really reflect proliferation? Eur J Nucl Med Mol Imaging (2008) 0.83
In vitro analysis of transport and metabolism of 4'-thiothymidine in human tumor cells. Nucl Med Biol (2014) 0.82
Optical imaging probes in oncology. Oncotarget (2016) 0.81
PET-specific parameters and radiotracers in theoretical tumour modelling. Comput Math Methods Med (2015) 0.80
[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. Proc Natl Acad Sci U S A (2016) 0.80
PET probes beyond (18)F-FDG. J Biomed Res (2014) 0.79
(18)F-FLT PET/CT imaging in a Wister rabbit inflammation model. Exp Ther Med (2014) 0.77
Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma. Invest New Drugs (2006) 0.77
Phosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retention. PLoS One (2014) 0.75
A novel in vitro assay to assess phosphorylation of 3'-[(18)F]fluoro-3'-deoxythymidine. Mol Imaging Biol (2011) 0.75
Multi-observation PET image analysis for patient follow-up quantitation and therapy assessment. Phys Med Biol (2011) 0.75
[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study. Ann Nucl Med (2015) 0.75
Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med (2003) 3.10